Related Experiment Video
Updated: Feb 26, 2026
Automated Analysis of Intracellular Phenotypes of Salmonella Using ImageJ
Published on: August 9, 2022
Current perspectives on invasive nontyphoidal Salmonella disease
Andrea H Haselbeck1, Ursula Panzner, Justin Im
1aInternational Vaccine Institute, Epidemiology Unit, Seoul, Republic of Korea bHospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam cDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom dInstitute of Tropical Medicine, Eberhard-Karls University Tübingen, Tübingen, Germany eDuy Tan University, Da Nang, Vietnam *Andrea H. Haselbeck and Ursula Panzner contributed equally to the writing of this article.
Invasive nontyphoidal Salmonella disease burden is better understood with new data. Vaccine development targeting Salmonella Typhimurium and Enteritidis is crucial for high-risk populations.
Area of Science:
- Infectious Diseases
- Epidemiology
- Vaccinology
Background:
- Invasive nontyphoidal Salmonella (iNTS) disease poses a significant global health challenge.
- Understanding host factors and disease burden is critical for effective control strategies.
Purpose of the Study:
- To review recent literature on the burden of iNTS disease and associated host factors.
- To discuss current progress and needs in iNTS vaccine development.
Main Methods:
- PubMed search of scientific literature published in the past 2 years.
- Inclusion of search terms covering disease, incidence, prevalence, host factors, and vaccination.
Main Results:
- Updated global estimates of iNTS disease burden, with new data from Africa, Asia, and Latin America.
- Identification of Salmonella Typhimurium sequence type 313 as an emergent pathogen in Africa, showing increased pathogenicity.
- Evidence suggests a bivalent vaccine targeting Salmonella Typhimurium and Enteritidis could reduce disease burden in at-risk groups.
Conclusions:
- Enhanced surveillance in Asia and Latin America is needed to fill data gaps on iNTS burden and antimicrobial resistance.
- Prioritizing resources for the development of an iNTS vaccine is essential.
